Thursday, 27 January 2022

Australia's most trusted
source of pharma news

Thursday, 27 January 2022

Covid wars: Pfizer vs MSD

Posted 1 December 2021 AM

Competition for market share in the Covid oral antiviral space is heating up with MSD hitting a speed bump, forced to downgrade the efficacy of Lagevrio, while Pfizer is boosting production for Paxlovid, ahead of what it expects is a surge in demand. 

In an interview on CNBC on Monday, Pfizer CEO Albert Bourla confirmed the company had increased planned production from 50 million doses to 80 million doses - confident Paxlovid will maintain high efficacy against Omicron and future variants of Covid.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.